| Type 2 Diabetes Mellitus |
1 |
1 |
| Cardiovascular Risk Management |
0 |
0.99 |
| Cardiovascular disease |
0 |
0.78 |
| Hypertension |
0 |
0.65 |
| Heart Failure (HF) |
0 |
0.38 |
| Angiotensin II Receptor Blockade |
0 |
0.33 |
| Receptors |
0 |
0.31 |
| Cerebrovascular Accident |
0 |
0.23 |
| ACE Inhibitor |
0 |
0.22 |
| Antihypertensive Agents |
0 |
0.16 |
| Aspirin |
0 |
0.16 |
| Blood |
0 |
0.16 |
| Clinical Research |
0 |
0.16 |
| Europe |
0 |
0.16 |
| Heart |
0 |
0.16 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.16 |
| Patient History |
0 |
0.16 |
| Statins |
0 |
0.98 |
| Stress |
0 |
0.16 |
| Lipids Management |
0 |
0.13 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.08 |
| HIV Infection |
0 |
0.08 |